Cargando…
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
OBJECTIVE: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 receptor agonists (dulaglutide and liraglutide) among patients with type 2 diabetes mellitus (T2DM) in the UK. METHODS: In-per...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646588/ https://www.ncbi.nlm.nih.gov/pubmed/26635470 http://dx.doi.org/10.2147/PPA.S90842 |
_version_ | 1782400956412985344 |
---|---|
author | Gelhorn, Heather L Poon, Jiat-Ling Davies, Evan W Paczkowski, Rosirene Curtis, Sarah E Boye, Kristina S |
author_facet | Gelhorn, Heather L Poon, Jiat-Ling Davies, Evan W Paczkowski, Rosirene Curtis, Sarah E Boye, Kristina S |
author_sort | Gelhorn, Heather L |
collection | PubMed |
description | OBJECTIVE: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 receptor agonists (dulaglutide and liraglutide) among patients with type 2 diabetes mellitus (T2DM) in the UK. METHODS: In-person interviews were conducted in the UK to administer a DCE to patients with self-reported T2DM, naïve to treatment with injectable medications. The DCE examined six attributes of T2DM treatment each described by two levels: “dosing frequency,” “hemoglobin A1c change,” “weight change,” “type of delivery system,” “frequency of nausea,” and “frequency of hypoglycemia.” Part-worth utilities were estimated using random effects logit models and were used to calculate relative importance (RI) values for each attribute. A chi-square test was used to determine differences in preferences for dulaglutide versus liraglutide profiles. RESULTS: A total of 243 participants [mean age: 60.5 (standard deviation 10.9) years; 76.1% male; mean body mass index: 29.8 (standard deviation 5.4) kg/m(2)] completed the study. RI values for the attributes in rank order were: “dosing frequency” (41.6%), “type of delivery system” (35.5%), “frequency of nausea” (10.4%), “weight change” (5.9%), “hemoglobin A1c change” (3.6%), and “frequency of hypoglycemia” (3.0%). Significantly more participants preferred the dulaglutide profile (83.1%) compared with the liraglutide profile (16.9%; P<0.0001). CONCLUSION: This study elicited patients’ preferences for attributes and levels representing the actual characteristics of two specific glucagon-like peptide-1 medications. In this context, dosing frequency and type of delivery system were most important, accounting for over 75% of the RI. While previous studies have identified efficacy as highly important in T2DM medication decisions, this study suggests that when differences in efficacy between medications are small, other treatment features (eg, dosing frequency and delivery system) are of much greater importance to patients. |
format | Online Article Text |
id | pubmed-4646588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46465882015-12-03 Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK Gelhorn, Heather L Poon, Jiat-Ling Davies, Evan W Paczkowski, Rosirene Curtis, Sarah E Boye, Kristina S Patient Prefer Adherence Original Research OBJECTIVE: To use a discrete choice experiment (DCE) to evaluate preferences for the actual treatment features and overall profiles of two injectable glucagon-like peptide-1 receptor agonists (dulaglutide and liraglutide) among patients with type 2 diabetes mellitus (T2DM) in the UK. METHODS: In-person interviews were conducted in the UK to administer a DCE to patients with self-reported T2DM, naïve to treatment with injectable medications. The DCE examined six attributes of T2DM treatment each described by two levels: “dosing frequency,” “hemoglobin A1c change,” “weight change,” “type of delivery system,” “frequency of nausea,” and “frequency of hypoglycemia.” Part-worth utilities were estimated using random effects logit models and were used to calculate relative importance (RI) values for each attribute. A chi-square test was used to determine differences in preferences for dulaglutide versus liraglutide profiles. RESULTS: A total of 243 participants [mean age: 60.5 (standard deviation 10.9) years; 76.1% male; mean body mass index: 29.8 (standard deviation 5.4) kg/m(2)] completed the study. RI values for the attributes in rank order were: “dosing frequency” (41.6%), “type of delivery system” (35.5%), “frequency of nausea” (10.4%), “weight change” (5.9%), “hemoglobin A1c change” (3.6%), and “frequency of hypoglycemia” (3.0%). Significantly more participants preferred the dulaglutide profile (83.1%) compared with the liraglutide profile (16.9%; P<0.0001). CONCLUSION: This study elicited patients’ preferences for attributes and levels representing the actual characteristics of two specific glucagon-like peptide-1 medications. In this context, dosing frequency and type of delivery system were most important, accounting for over 75% of the RI. While previous studies have identified efficacy as highly important in T2DM medication decisions, this study suggests that when differences in efficacy between medications are small, other treatment features (eg, dosing frequency and delivery system) are of much greater importance to patients. Dove Medical Press 2015-11-09 /pmc/articles/PMC4646588/ /pubmed/26635470 http://dx.doi.org/10.2147/PPA.S90842 Text en © 2015 Gelhorn et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Gelhorn, Heather L Poon, Jiat-Ling Davies, Evan W Paczkowski, Rosirene Curtis, Sarah E Boye, Kristina S Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title | Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title_full | Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title_fullStr | Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title_full_unstemmed | Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title_short | Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK |
title_sort | evaluating preferences for profiles of glp-1 receptor agonists among injection-naïve type 2 diabetes patients in the uk |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646588/ https://www.ncbi.nlm.nih.gov/pubmed/26635470 http://dx.doi.org/10.2147/PPA.S90842 |
work_keys_str_mv | AT gelhornheatherl evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk AT poonjiatling evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk AT daviesevanw evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk AT paczkowskirosirene evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk AT curtissarahe evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk AT boyekristinas evaluatingpreferencesforprofilesofglp1receptoragonistsamonginjectionnaivetype2diabetespatientsintheuk |